Skip to Main Content

Good morning everyone, from STAT reporter Andrew Joseph here filling in for Ed. Or, if I’m being honest, good afternoon. No, this is not some snap in the space-time continuum. Rather, I’m writing to you from STAT’s new outpost in London. That’s right, STAT’s gone global. I’ve moved over here to expand our coverage of European biopharma and health news, so do get in touch if you have ideas for what I should be taking a look at. Now, enough delay. On to the pharma headlines you seek. …

Eli Lilly’s drug Mounjaro for type 2 diabetes helped people who are also overweight or obese lose up to 15.7% of their body weight, in a new study that could pave the way for Lilly to promote the drug as a weight-loss treatment, the Wall Street Journal writes. Lilly said that with the new data, it will complete in the coming weeks an application to the U.S. Food and Drug Administration to market Mounjaro as an anti-obesity treatment, which could enable an FDA decision by the end of the year. Lilly’s Mounjaro was approved last year as a diabetes treatment, though some people already use it off-label for weight loss. Also Thursday, Lilly raised its annual revenue and profit forecasts after topping first-quarter sales estimates, thanks to demand for Mounjaro, Reuters tells us.


We’ve got a bevy of other earnings headlines this morning, also courtesy of Reuters: French drugmaker Sanofi posted better-than-expected earnings for the first quarter as continued gains from the anti-inflammatory drug Dupixent more than offset declining sales from an established multiple sclerosis drug. Merck posted better-than-expected first-quarter results on the strength of its blockbuster cancer immunotherapy Keytruda and HPV vaccine Gardasil. AstraZeneca beat expectations for first-quarter profit and revenue, as buoyant sales of the cancer treatment Imfinzi and strong demand for its roster of drugs in emerging markets helped to offset dwindling Covid product sales. And Bristol Myers Squibb said its first-quarter sales fell from last year, hurt by generic competition for its cancer drug Revlimid.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.